Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Sling Therapeutics | Sep 2026Led | $123 MSeries C | |
Solstice Oncology | Sep 2026Participated | $225 MSeries A | |
Kynexis | Aug 2026Participated | $46 MSeries A | |
Slate Medicines | Aug 2026Participated | $245 MOther Equity | |
Novo | Aug 2026Led | $31 MOther Equity | |
Expedition Therapeutics | Aug 2026Participated | $115 MSeries B | |
RQ Bio | Jun 2026Participated | $115 MSeries A | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
CellCentric | May 2026Participated | $220 MSeries D | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Mestag Therapeutics | Mar 2026Participated | $40 MOther Equity | |
Tropic Biosciences | Mar 2026Led | $105 MSeries C | |
Sling Therapeutics | Sep 2026Led | $123 MSeries C | |
Solstice Oncology | Sep 2026Participated | $225 MSeries A | |
Kynexis | Aug 2026Participated | $46 MSeries A | |
Slate Medicines | Aug 2026Participated | $245 MOther Equity | |
Novo | Aug 2026Led | $31 MOther Equity | |
Expedition Therapeutics | Aug 2026Participated | $115 MSeries B | |
RQ Bio | Jun 2026Participated | $115 MSeries A | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
CellCentric | May 2026Participated | $220 MSeries D | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Mestag Therapeutics | Mar 2026Participated | $40 MOther Equity | |
Tropic Biosciences | Mar 2026Led | $105 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 6 | 0 |
| Series A | 32 | 16 |
| Series B | 21 | 28 |
| Series C+ | 12 | 22 |
| Other Equity | 6 | 8 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Mar '08 | 1 |
| Apr '08 | 0 |
| May '08 | 0 |
| Jun '08 | 0 |
| Jul '08 | 0 |
| Aug '08 | 0 |
| Sep '08 | 0 |
| Oct '08 | 0 |
| Nov '08 | 0 |
| Dec '08 | 0 |
| Jan '09 | 0 |
| Feb '09 | 0 |
| Mar '09 | 0 |
| Apr '09 | 0 |
| May '09 | 0 |
| Jun '09 | 0 |
| Jul '09 | 0 |
| Aug '09 | 0 |
| Sep '09 | 1 |
| Oct '09 | 0 |
| Nov '09 | 0 |
| Dec '09 | 0 |
| Jan '10 | 1 |
| Feb '10 | 0 |
| Mar '10 | 1 |
| Apr '10 | 0 |
| May '10 | 1 |
| Jun '10 | 0 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 0 |
| Oct '10 | 0 |
| Nov '10 | 1 |
| Dec '10 | 1 |
| Jan '11 | 1 |
| Feb '11 | 1 |
| Mar '11 | 0 |
| Apr '11 | 1 |
| May '11 | 0 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 0 |
| Sep '11 | 3 |
| Oct '11 | 2 |
| Nov '11 | 2 |
| Dec '11 | 1 |
| Jan '12 | 0 |
| Feb '12 | 0 |
| Mar '12 | 1 |
| Apr '12 | 1 |
| May '12 | 1 |
| Jun '12 | 0 |
| Jul '12 | 1 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 1 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 1 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 1 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 2 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 1 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 1 |
| Oct '14 | 0 |
| Nov '14 | 1 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 1 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 3 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 1 |
| Feb '16 | 1 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 1 |
| Feb '17 | 1 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 1 |
| Aug '17 | 1 |
| Sep '17 | 1 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 2 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 1 |
| Apr '18 | 1 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 1 |
| Sep '18 | 0 |
| Oct '18 | 2 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 1 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 1 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 3 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 3 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 1 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 1 |
| Nov '21 | 1 |
| Dec '21 | 3 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 1 |
| Apr '22 | 1 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 1 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 2 |
| Apr '23 | 1 |
| May '23 | 1 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 4 |
| Nov '23 | 2 |
| Dec '23 | 0 |
| Jan '24 | 2 |
| Feb '24 | 1 |
| Mar '24 | 2 |
| Apr '24 | 0 |
| May '24 | 3 |
| Jun '24 | 0 |
| Jul '24 | 3 |
| Aug '24 | 1 |
| Sep '24 | 3 |
| Oct '24 | 4 |
| Nov '24 | 0 |
| Dec '24 | 2 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 3 |
| May '25 | 2 |
| Jun '25 | 1 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 2 |
| Oct '25 | 3 |
| Nov '25 | 3 |
| Dec '25 | 2 |
| Jan '26 | 2 |
| Feb '26 | 2 |
| Mar '26 | 2 |
| Apr '26 | 1 |
| May '26 | 2 |
| Jun '26 | 1 |
| Jul '26 | 0 |
| Aug '26 | 4 |
| Sep '26 | 2 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 147 |
| Space & Frontier Tech | 3 |
| Developer Tools | 3 |
| Networks, Cloud & Communication | 2 |
| Food & Agriculture | 2 |
| Clean Energy & Sustainability | 2 |
| Consumer & Lifestyle | 2 |
| Fintech | 1 |
| Enterprise Software | 1 |
| Manufacturing | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 6 |
| $10M-$25M | 21 |
| $25M-$50M | 42 |
| $50M-$100M | 36 |
| $100M-$250M | 42 |
| $250M-$500M | 2 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 84 |
| United States | 58 |
| Canada | 5 |
| Israel | 3 |
| India | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 20 |
| Novo Holdings | 15 |
| BioGeneration Ventures | 14 |
| Novartis | 13 |
| Sofinnova Partners | 13 |
| Atlas Venture | 12 |
| Gilde Healthcare | 12 |
| OrbiMed | 11 |
| EQT Life Sciences (LSP) | 9 |
| Sofinnova Ventures | 9 |
| Ysios Capital | 9 |
| Advent Life Sciences | 8 |
| Morningside | 7 |
| Polaris Partners | 7 |
| Syncona | 7 |
| CD-Venture | 6 |
| Eli Lilly and Company | 6 |
| HealthCap | 6 |
| Jeito Capital | 6 |
| Longwood Fund | 6 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 77 | 51% |
| Participating | 74 | 49% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 28 | 36% |
| Co-led | 49 | 64% |
Team
Venture Partner
General Partner
General Partner
Managing Director
Venture Partner
Venture Partner
Principal
Partner
Founder, Co-owner & Managing Partner
Operating Partner
Chief Financial Officer